Board Member
Viking Therapeutics, Inc. (VKTX)Equibles does not estimate personal net worth.
Get an email with a short summary when Viking Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get VKTX alertsBrian Lian is recorded as Board Member and CEO at Viking Therapeutics, Inc. (VKTX). The newest filing on record that lists Brian Lian as Board Member and CEO at Viking Therapeutics, Inc. (VKTX) is dated April 1, 2026. The proxy statement of Viking Therapeutics, Inc. reports total compensation of $21,269,833 for Brian Lian in fiscal 2025, including a base salary of $672,000. Disclosed compensation is on record for 8 fiscal years. Brian Lian has spoken on 25 earnings calls across 1 company, most recently for Viking Therapeutics, Inc. on July 29, 2026. Viking Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Viking Therapeutics, Inc. includes Greg Zante (CFO), Marianne Mancini (COO), Brian Lian, Ph.D. (Board Member) and 5 others.
“Thanks, Stephanie, and good afternoon to everyone listening in by phone or on the webcast. Today, we'll review our financial results for the second quarter and six months ended June 30th, 2026, and review recent updates across our pipeline, programs, and organization.”
“Thanks, Stephanie, and good afternoon to everyone listening in by phone or on the webcast. Today, we'll review our financial results for the first quarter ended March 31, 2026, and review recent progress with our pipeline programs and operations.”
“Thanks, Stephanie, and good afternoon to everyone listening in by phone or on the webcast. Today, we'll review our financial results for the fourth quarter and full year ended December 31, 2025, and review recent progress with our development programs and operations.”
“Thanks, Stephanie, and good afternoon to everyone listening in by phone or on the webcast. Today, we'll review our financial results for the third quarter and 9 months ended September 30, 2025, and review recent progress with our development programs and operations.”
“Thanks, Stephanie, and good afternoon to everyone listening in by phone or on the webcast. Today, we'll review our financial results for the second quarter and six months ended June 30, 2025, and provide an update on recent progress with our development programs and operations.”
Start not stated–present
Last confirmed April 1, 2026
Start not stated–present
Last confirmed April 1, 2026
Biotechnology · Healthcare
Board Member, CEO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Viking Therapeutics, Inc. (VKTX) | Chief Executive Officer | $672,000 | $21,269,833 |
| 2024 | Viking Therapeutics, Inc. (VKTX) | Chief Executive Officer | $640,000 | $14,298,554 |
| 2023 | Viking Therapeutics, Inc. (VKTX) | Chief Executive Officer | $615,000 | $12,628,061 |
| 2022 | Viking Therapeutics, Inc. (VKTX) | Chief Executive Officer | $611,800 | $5,411,291 |
| 2021 | Viking Therapeutics, Inc. (VKTX) | Chief Executive Officer | $594,000 | $4,059,119 |
| 2020 | Viking Therapeutics, Inc. (VKTX) | Chief Executive Officer | $577,000 | $5,187,448 |
| 2019 | Viking Therapeutics, Inc. (VKTX) | Chief Executive Officer | $525,000 | $3,512,119 |
| 2018 | Viking Therapeutics, Inc. (VKTX) | Chief Executive Officer | $485,000 | $1,403,283 |
